Neuland Laboratories share news, announcements and annual reports
NSE: NEULANDLABBSE: 524558Pharmaceuticals & BiotechnologySmall Cap
Neuland Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jul 1994 on BSE, Oct 2008 on NSE
Last close ₹19,700.00up ₹420.00 (2.18%)BSE ₹19,701.10
Share price at the NSE close on 30 Oct 2026. Previous close ₹19,280.00.
30 Oct: open ₹19,345.00, high ₹19,920.00, low ₹19,025.00
52-week range of traded prices to 30 Oct 2026
₹11,500.00Low, 23 Mar 2026₹24,225.00High, 9 Sep 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹25,275 Cr356th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 50.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 13.48
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.17%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 29.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 32.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.10
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 60,08043.6% delivered
Neuland Laboratories share news and announcements
837 announcements, routine notices left out, newest first. Page 12 of 17.
Jun 2017
May 2017
31 May · Meeting
30 May · Court Convened Meeting Updates
18 May · Declaration for audit reports with unmodified opinion(s)
15 May · Business
12 May · Board meeting
12 May · Business
12 May · Results
9 May · Court Convened Meeting Updates
8 May · Analysts
Apr 2017
30 Apr · Business
29 Apr · Business
24 Apr · Business
19 Apr · Business
11 Apr · Rating
5 Apr · Meeting
Mar 2017
30 Mar · News Verification
Exchange has sought clarification from Neuland Laboratories Limited with respect to recent news item captioned "Neuland labs close to acquiring intermediates, API facility". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such negotiations were taking place and b) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.29 Mar · Legal
The exchange asked on 28 Mar 2017
28 Mar · Analysts
27 Mar · Analysts
1 Mar · News Verification
Exchange has sought clarification from Neuland Laboratories Limited with respect to recent news item captioned "US FDA grants priority review for SD-809." In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Feb 2017
21 Feb · Meeting
10 Feb · Business
10 Feb · Results
6 Feb · Analysts
Jan 2017
Dec 2016
2 Dec · Statement on Impact of Audit Qualifications
Nov 2016
30 Nov · Analysts